Company ProfilePremium

INOVIQ Limited (formerly BARD1 Life Sciences Limited)

Company Profile Analysis

Ticker: IIQ.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
INOVIQ Limited - Company showcase

Year Founded & Workforce

1983

INOVIQ Limited logo

INOVIQ Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

INOVIQ Limited Overview

INOVIQ is a micro-cap Australian biotechnology company built around a proprietary exosome (small extracellular vesicle) isolation platform, EXO-NET®. It has two small commercial revenue lines. The first is EXO-NET research-use exosome capture products, distributed worldwide by Promega Corporation. The second is the hTERT immunocytochemistry test, an adjunct to urine cytology for bladder cancer, sold directly to US laboratories. Total product revenue was only A$0.43m in FY2026. The company's value rests on its pipeline. The lead asset is EXO-OC™, an exosome-miRNA plus CA125 blood test for early ovarian cancer detection, which INOVIQ intends to launch first as a US Laboratory Developed Test (LDT). The second is a preclinical CAR-exosome (CAR-NK-EV) cell-free therapy platform targeting triple-negative breast, lung and ovarian cancers, with first-in-human studies targeted for 2028. It also holds the SubB2M-based neuCA15-3 breast cancer monitoring assay. INOVIQ ended FY2026 with A$9.35m in cash and no material debt. In July 2026 it suffered a significant setback when a 1,200-sample EXO-OC validation study failed on sample quality.


Company's own description (Annual Report FY2026)

The FY2026 Directors' Report defines the group's principal activities as developing and commercialising diagnostics and therapeutics for cancer. It describes a portfolio of commercial exosome isolation products and an adjunct bladder cancer test, clinical-stage diagnostics for breast and ovarian cancers, and a preclinical CAR-exosome therapeutic program for solid tumours. The Review of Operations calls INOVIQ an integrated diagnostics and therapeutics company. Its core technology isolates extracellular vesicles with high specificity and purity, supporting minimally invasive early cancer detection and targeted, cell-free solid tumour treatment. The CEO's report frames the strategy as moving from research tools to diagnostics and therapeutics, aiming at larger global markets with greater clinical impact.

Independent characterisation

In substance, INOVIQ is a pre-commercial, platform-based oncology biotech with a small product revenue "tail." It has three distinct economic engines:

  1. Research tools (EXO-NET®, NEURO-NET, customNET). These are bead-based exosome capture reagents sold for research use only (RUO). Revenue comes from product sales to Promega, the exclusive global distribution partner, which resells to academic and government institutes, biopharma companies and clinical laboratories. Promega reported 90 EXO-NET customers by the end of FY2026, up from about 60 in mid-2025. EXO-NET revenue nevertheless fell to A$138,045 in FY2026 from A$253,261 in FY2025, which the company attributes to channel inventory timing.

  2. Legacy IVD (hTERT ICC test). This line was inherited from the 2020 acquisition of Sienna Cancer Diagnostics. The test is registered as a Class I IVD in the US and sold directly to pathology laboratories. Revenue has flattened at about A$0.29m a year, and management expects it to stay flat in FY2027 because the market is small and competition is rising.

  3. Pipeline (diagnostics and therapeutics). This includes EXO-OC™ (ovarian cancer early detection), neuCA15-3 (breast cancer monitoring, based on SubB2M), and the CAR-exosome platform (EEV-001 for TNBC, EEV-002 for NSCLC and EEV-003 for ovarian cancer). Planned monetisation runs through LDT laboratory partnering in the US for EXO-OC, licensing or partnering for neuCA15-3, and eventual clinical development, likely partnered, for CAR-exosomes.

Revenue model mix (FY2026)

Revenue typeFY2026 (AUD)Share of product revenueModel
hTERT test (product sales, US direct)294,00268.0%Product, direct to labs
EXO-NET (product sales to Promega)138,04532.0%Product, distributor model
Licensing / royalty income00%A royalty entitlement on any future BARD1 lung test sales exists under the 2022 settlement; no income recognised
Service / subscription00%Not applicable
Total product revenue432,047100%—

Source: AR FY2026, Review of Operations and Statement of Comprehensive Income. Shares are derived.

Non-operating "other income" (A$2.18m in FY2026) is far larger than product revenue. It consisted mainly of the R&D Tax Incentive refund accrual (A$1.78m) and interest income (A$0.40m).

Value chain position, customers and end-markets

Value chain: INOVIQ sits upstream as an IP owner and reagent and assay developer. It uses distributors (Promega) and is seeking a US CLIA-certified laboratory partner for EXO-OC. Manufacturing of EXO-NET was centralised in its Melbourne laboratory in FY2023, according to the HY2023 report. For CAR-exosomes, the company is selecting a CDMO and sourcing GMP-compliant cells (AR FY2026).

Customer types: academic and government research institutes, biopharma, clinical laboratories and hospitals (EXO-NET); US pathology laboratories (hTERT); and prospectively US reference laboratories, payers and women at high risk of ovarian cancer (EXO-OC).

End-markets: exosome and extracellular vesicle research tools; liquid biopsy and cancer diagnostics (ovarian, breast, bladder); and cell-free oncology therapeutics.

Strategy

Stated strategy (AR FY2026, paraphrased themes)

Mission: to improve patient lives through earlier cancer detection and more effective treatment, built on exosome technologies.

Platform leverage: use one exosome isolation and engineering platform across research tools, diagnostics and therapeutics, so that multiple products share the same underlying technology.

Staged value ladder: move from revenue-generating research tools to higher-value diagnostics (EXO-OC as a US LDT first, then IVD) and therapeutics (CAR-exosomes toward first-in-human studies).

Partner-led commercialisation: Promega for research tools; a US CLIA laboratory for EXO-OC; partners for neuCA15-3.

Capital discipline: concentrate spending on EV diagnostic and therapeutic programs.

FY2027 priorities (AR FY2026, Outlook)

  1. Complete EXO-OC™ development and validation in average-risk and high-risk groups.

  2. Progress EXO-OC™ toward LDT readiness and US laboratory partnering.

  3. Advance CAR-exosome therapeutics toward manufacturing readiness and future clinical development.

  4. Maintain disciplined capital allocation across EV diagnostic and therapeutic programs.

  5. Deliver milestones that support long-term shareholder value.

For comparison, the FY2026 priorities set in AR FY2025 were: expand EXO-NET and grow revenue; advance EXO-OC toward commercialisation; move CAR-exosomes into in vivo efficacy studies for breast cancer; and execute strategic partnerships. Delivery against these was mixed. In vivo CAR-exosome proof of concept was achieved. EXO-NET revenue fell. EXO-OC validation failed on sample quality. No diagnostic commercialisation partnership was signed.

Strategic initiatives in the last 24 months (October 2024 to October 2026)

DateInitiativeTypeStatus
1 Apr 2025UQ research collaboration with Prof Carlos Salomon Gallo on ovarian exosomal biomarkersR&D partnershipConverted to an exclusive licence (Sep 2025)
May 2025neuCA15-3 peer-reviewed validation (Breast Cancer Research and Treatment)Clinical evidenceMoving to an automated platform
FY2025 to FY2026CAR-exosome in vivo program with Peter MacCallum Cancer CentreR&D collaborationIn vivo TNBC data reported 22 Dec 2025
26 Sep 2025Exclusive worldwide licence from UniQuest for ovarian exosomal biomarkersIP in-licensingExecuted
13 Oct 2025A$9.5m placement plus SPP (A$10.2m total) with Tian An Medicare as cornerstoneCapital / strategic investorCompleted November 2025
Oct to Dec 2025Board renewal: Gunzburg returns as ChairGovernanceCompleted
Jan 2026CSO appointment (Dr Rebecca Lim) bringing CDMO and IND experienceCapability buildCompleted
FY2026EXO-OC expanded clinical study (up to 2,000 samples)Clinical validationFailed on sample quality (1 Jul 2026); redesign under way
May 2026EXO-OC PCT patent applicationIPFiled 29 May 2026
FY2027CAR-exosome manufacturing readiness (GMP cells, CDMO selection, dual-action CAR-exosomes)Platform investmentIn progress
FY2027US LDT partner discussions for EXO-OCCommercial partneringActive discussions; no agreement announced

ESG commitments: none published.

Cost programs: no formal cost-reduction program with targets has been announced.

Medium-term targets and guidance

INOVIQ gives no revenue or earnings guidance. Its non-financial milestones are an independent EXO-OC validation study (FY2027), technology transfer to a US CLIA laboratory, and CAR-exosome first-in-human studies targeted for 2028. Management guided hTERT revenue to be flat in FY2027.

Products & Services

Pipeline overview (AR FY2026, Product Portfolio page)

ProgramCategoryIndicationIntended useStage (FY2026)
EXO-NET®Research toolPan-exosome isolationRUO biomarker discovery and diagnostics developmentIn market (global via Promega)
NEURO-NETResearch toolBrain-derived exosome isolationNeurological disease research (validated in Parkinson's disease)Research tool, evaluations
customNETResearch toolBespoke exosome capturePartner-specific applicationsEvaluations
hTERT ICC testIVDBladder cancerAdjunct to urine cytologyIn market (US Class I IVD)
EXO-OC™ LDTDiagnosticOvarian cancerEarly detection, high-risk womenClinical (validation reset after July 2026)
EXO-OC™ IVDDiagnosticOvarian cancerScreening, average-risk womenEarlier stage; follows the LDT
neuCA15-3Diagnostic (SubB2M)Breast cancerMonitoringAssay development / clinical validation
EEV-001Therapeutic (CAR-exosome)Triple-negative breast cancerEGFR-targeted CAR-NK-EV therapyPreclinical (in vitro and in vivo proof of concept)
EEV-002Therapeutic (CAR-exosome)Non-small cell lung cancerCAR-exosome therapyPreclinical (in vitro)
EEV-003Therapeutic (CAR-exosome)Ovarian cancerCA125- and EGFR-targeted CAR-exosomesPreclinical (in vitro)
EXO-ACE™Manufacturing platformTherapeutic exosomesScalable CAR-exosome productionPublished proof of concept (JoVE, Oct 2025)
BARD1 autoantibody (breast and ovarian)Diagnostic IPBreast and ovarian cancerLegacy programUnder review, de-prioritised (IP retained)

Product-by-product detail

EXO-NET® pan-exosome capture tool

Description: A proprietary "Molecular NET" capture technology that isolates exosomes from body fluids. The company claims advantages in speed, specificity, purity, yield and scalability over conventional methods such as ultracentrifugation and size-exclusion.

Target customers: EV researchers in academia and government, biopharma biomarker groups, and clinical laboratories and hospitals.

Launch: RUO product commercialised in Australia first, then launched in the US in October 2022. A high-throughput (HT) EXO-NET system was developed with Promega in FY2023. Promega has been the global distribution partner since 2024, placing its first order in June 2024 and its third order during FY2026.

Customer base: about 60 Promega customers by mid-2025 (Roic.ai summary of company disclosures) and 90 by the end of FY2026 (AR FY2026). Adoption was strongest in Europe, then North America, then Asia-Pacific.

Pricing: Not publicly disclosed.

Revenue: A$138,045 in FY2026, down 45.5%.

Pipeline extension: An EXO-NET/RNA combination product for automated workflows was being developed with Promega, with launch targeted for Q3 FY2026 (Roic.ai summary of company materials). The FY2026 annual report sections reviewed did not confirm the launch.

NEURO-NET

Description: An EXO-NET variant that selectively captures brain-derived (neuronal) exosomes from blood. It was further validated in Parkinson's disease during FY2025 (HY2025 report).

Target customers: Neuroscience and neurodegenerative disease researchers and diagnostic developers.

Status: Research tool under evaluation. Revenue not separately disclosed.

customNET

Description: Bespoke capture formats developed with partners. Multiple evaluations were run in FY2026 across cancer, cardiology and neurology (AR FY2026).

hTERT ICC test

Description: An immunocytochemistry assay that detects human telomerase reverse transcriptase in cytopathology samples. It is used alongside urine cytology to resolve indeterminate results and flag patients at higher bladder cancer risk.

Regulatory: Registered as a Class I IVD medical device in the US.

Channel: Sold directly to US laboratories. The FY2021 quarterly reports referred to a former distributor, StatLab Medical Products.

Revenue: A$294,002 in FY2026, flat. Management expects flat FY2027 revenue because of limited market size and new competing products.

Origin: Acquired with Sienna Cancer Diagnostics in July 2020.

EXO-OC™ ovarian cancer test (lead diagnostic)

Description: A blood test that isolates exosomes with EXO-NET and combines several exosomal miRNA biomarkers with plasma CA125 in an AI/machine-learning algorithm.

Performance history: - 498-sample single-site retrospective study (ASX, 2 June 2025): 100% sensitivity for Stage I/II and 77% for all stages at 99.6% specificity.

  • Optimised algorithm (FY2026): 92.3% sensitivity for Stage I/II and 92.5% for all stages at 98% specificity. The training set had 338 samples and the test set 146 (AR FY2026).

  • Expanded study (up to 2,000 samples planned; first stage about 1,200 samples from five commercial biorepositories). Sample analysis began in April 2026. On 1 July 2026 the study was declared unsuitable for performance evaluation. One provider supplied 616 samples, including 69% of cancer cases, and those samples showed reduced protein and miRNA levels consistent with degradation. Pre-analytical variability was also significant across all providers. The company states these issues were unrelated to the test or EXO-NET. The June 2026 quarterly report put the cost of the study at about A$850k.

Commercial plan: Launch first as a US LDT through a CLIA-certified laboratory partner for high-risk women (BRCA1/2 carriers, Lynch syndrome, strong family history). Develop later as an IVD for average-risk screening.

IP: Provisional patent converted to an International (PCT) application on 29 May 2026. An exclusive worldwide licence to University of Queensland ovarian exosomal biomarkers was obtained from UniQuest on 26 September 2025.

Pricing: Not disclosed.

neuCA15-3 breast cancer monitoring test (SubB2M platform)

Description: Pairs a CA15-3 monoclonal antibody with SubB2M, an engineered protein that binds the tumour-associated glycan Neu5Gc. The aim is to detect tumour-derived CA15-3 more specifically and reduce false positives.

Performance: 81% sensitivity and 93% specificity across all stages, major subtypes and post-treatment monitoring (AR FY2026). Peer-reviewed validation was published in Breast Cancer Research and Treatment in May 2025.

Next steps: Transfer to a bead-based chemiluminescent assay on high-throughput automated platforms, run an in-clinic monitoring study, and secure a commercialisation partner.

CAR-exosome therapeutics (EEV-001, EEV-002, EEV-003)

Description: Cell-free therapy derived from CAR-engineered NK cells. The resulting extracellular vesicles inherit the parent cells' tumour targeting and cytotoxicity. Potential advantages claimed include off-the-shelf manufacture, safety and cost compared with autologous CAR-T.

Data: - FY2025: 88% killing of TNBC and NSCLC cells in vitro (Appendix 4E FY2025).

  • 18 September 2025: more than 90% TNBC cell killing within 10 hours in vitro.

  • 22 December 2025: in vivo TNBC mouse model showed 61.5% tumour burden reduction with EGFR-CAR-NK-EVs, compared with 24.5% for unmodified NK-EVs. No adverse effects were observed, and targeting was precise.

  • June 2026: ovarian cancer cell lines. CA125-CAR-exosomes killed more than 90% of OVCAR-3 and Caov-3 cells within 48 hours, and EGFR-CAR-exosomes killed more than 80%. Both killed about 50% of aggressive SK-OV-3 cells.

Manufacturing: Proprietary EXO-ACE™ platform (JoVE publication, 1 October 2025). FY2027 work covers GMP cell sourcing, CDMO selection and next-generation dual-action CAR-exosomes.

Timeline: First-in-human studies targeted for 2028.

Collaborator: Peter MacCallum Cancer Centre for in vivo TNBC studies (Roic.ai summary of company disclosures).

BARD1 autoantibody tests (legacy)

  • BARD1-Ovarian and BARD1-Breast autoantibody tests were the company's founding programs. The lung test IP was transferred to the founders under the November 2022 settlement, with INOVIQ keeping a royalty. The breast and ovarian IP was retained, but those programs are not prioritised in the current pipeline.

Financial Narrative

Sources: Appendix 4E and Annual Reports FY2022 to FY2026. Balance sheet and cash flow totals for FY2022 to FY2024 are cross-checked against Stockopedia's annual report extracts. All figures are AUD under AASB/IFRS.

Income statement

Revenue CAGR FY2022 to FY2026 was about 11.8% a year, from a very small base. The FY2022 loss is the audited figure. It includes non-cash impairments and replaced the unaudited A$6.5m loss in the August 2022 Appendix 4E (INOVIQ release, 28 September 2022).

Detailed P&L, FY2025 to FY2026 (A$)

Source: AR FY2026, Consolidated Statement of Comprehensive Income (p.32).

Derived EBITDA (analyst calculation, A$ millions). Method: loss before tax, plus amortisation (intangibles and patents), plus depreciation (right-of-use, buildings, plant), plus lease interest, minus interest income. Inputs are from the AR FY2026 expense disclosures.

Expense trend, FY2023 to FY2026 (A$ millions)

Sources: AR FY2024 (p.16), AR FY2025 (p.14), AR FY2026 (p.13). The FY2024 R&D figure is as reported in AR FY2024.

Commentary. The loss profile has stabilised at A$6.5m to A$7.5m a year since FY2024, after a peak in FY2022 caused by impairments. The FY2023 loss was swollen by legal costs: professional and legal fees reached A$2.15m in FY2023, versus A$0.61m in FY2024, mainly from defending the Supreme Court writ. The FY2026 mix is notable. G&A fell 8.4%, helped by a A$87k share-based payments credit after options cancelled on the former Chairman's resignation were reversed. R&D rose 43.5% to A$4.67m, with external contractor spend up to A$2.82m from A$1.69m, reflecting the EXO-OC clinical study and CAR-exosome work. The R&D Tax Incentive refund accrual of A$1.78m effectively funds about 38% of gross R&D spend. Product revenue covers less than 5% of operating expenditure, so the business depends entirely on equity funding and tax refunds.

Balance sheet

Sources: AR FY2026 (p.33) for FY2025 and FY2026; Stockopedia annual report extracts for FY2022 to FY2024. Equity for FY2022 to FY2024 is derived as total assets minus total liabilities.

Detailed FY2025 to FY2026 balance sheet (A$)

Debt and net cash (A$ millions)

Commentary. The balance sheet is clean, with no bank debt apart from a small equipment loan. However, accumulated losses reached A$70.2m against A$87.7m of contributed equity. Intangibles of A$7.7m (hTERT and Molecular NETs, plus patents) make up 41% of net assets and amortise at about A$0.96m a year. An impairment risk exists if the hTERT outlook deteriorates further. The right-of-use asset and lease liability both fell to zero at 30 June 2026. This suggests the Notting Hill lease either expired or moved to a short-term or new arrangement after balance date. The terms are not publicly disclosed in the material reviewed.

Cash flow

Sources: AR FY2026 cash flow statement (p.35) for FY2025 and FY2026; Stockopedia for FY2022 to FY2024.

FY2026 operating detail: product receipts were A$462,942; payments to suppliers and employees A$8,487,366; interest received A$397,388; and the R&D tax refund received A$1,267,738 (relating to FY2025). Financing comprised share issue proceeds of A$10,199,939, less issue costs of A$597,023, lease payments of A$178,653 and equipment loan repayments of A$38,045.

Cash runway (analyst estimate). FY2026 operating burn was A$6.38m including the FY2025 refund. Cash at 30 June 2026 was A$9.35m, with a further A$1.78m FY2026 R&D refund receivable expected in coming months. Assuming a similar spend level, this implies about 14 to 20 months of funding from 30 June 2026, which points to a probable capital need in 2027.

Ratios

ROE and ROA use average equity and average assets (FY2021 equity A$29.04m and total assets A$33.5m, from Stockopedia).

Not meaningful: ROIC, net debt/EBITDA and interest coverage are negative or meaningless because EBIT and EBITDA are negative and the company holds net cash. The cash conversion cycle is not meaningful because inventory (A$38k) and trade receivables tied to product sales are immaterial. Receivables are dominated by the R&D tax refund.

Inflection analysis. The financial trajectory has three phases.

  1. FY2021 to FY2022: post-merger integration and impairment. The Sienna acquisition, the BARD1 autoantibody review and impairments drove the FY2022 loss of A$18.2m.

  2. FY2023 to FY2025: operating discipline and first EXO-NET revenue. Losses fell to about A$6.5m to A$6.9m, and EXO-NET revenue grew from A$35k to A$253k.

  3. FY2026: reinvestment in clinical validation and therapeutics. R&D rose 43%, a A$10.2m raise was completed, but EXO-NET revenue fell back and the flagship validation study failed on sample quality.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityJurisdictionOwnershipRole

INOVIQ Limited

Australia

Parent (ASX-listed)

Group holding company; R&D; HQ and laboratory

Sienna Cancer Diagnostics Ltd

Australia

100%

Legacy Sienna entity (hTERT, NETs IP; Sienna Cancer Diagnostics® trademark)

INOVIQ Inc

United States

100%

US commercial operations (hTERT direct sales; EXO-NET US activity)

Product Lines

Product line (AUD)FY2023FY2024FY2025FY2026

hTERT test revenue

363,209333,255294,314294,002

EXO-NET revenue

34,984201,863253,261138,045

Total product revenue

398,193535,118547,575432,047

Segment Margins & Growth (%) and Revenue by Segment (%)

Metric (%)FY2023FY2024FY2025FY2026

hTERT YoY growth

0-8.2-11.7-0.1

EXO-NET YoY growth

0477.025.5-45.5

hTERT share of revenue

91.262.353.768.0

EXO-NET share of revenue

8.837.746.332.0

Income Statement and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Revenue (AUD Mn)

0.2770.3980.5350.5480.432

Revenue growth (%)

-40.943.934.42.3-21.1

Net loss after tax (AUD Mn)

-18.196-8.969-6.554-6.932-7.505

Basic EPS (AUD cents)

-20.03-9.75-7.09-6.23-5.69

Diluted EPS (AUD cents)

-20.03-9.75-7.09-6.23-5.69

Dividends per share (AUD cents)

00000

Net margin (%)

-6,575-2,252-1,225-1,266-1,737

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement (AUD) and Margin Analysis (%)

Line item (AUD)FY2025FY2026

Product revenue

547,575432,047

Cost of sales

-120,386-76,709

Gross profit

427,189355,338

Gross margin (%)

78.082.2

R&D Tax Incentive refund

1,267,7381,782,316

Interest and miscellaneous income

411,744399,788

General and administration

-5,313,080-4,867,071

Research and development

-3,254,552-4,669,680

Sales and marketing

-471,319-505,814

Total operating expenditure

-9,038,951-10,042,565

Loss before income tax

-6,932,280-7,505,123

Income tax

00

Loss after tax

-6,932,280-7,505,123

Foreign currency translation (OCI)

-76,684200,014

Total comprehensive loss

-7,008,964-7,305,109

Income Statement

Metric (AUD Mn)FY2025FY2026

Loss before tax

-6.932-7.505

Amortisation

0.9800.960

Depreciation

0.4000.370

Lease interest

0.0220.021

Interest income

-0.412-0.400

EBITDA (derived)

-5.942-6.554

Key Financials

MetricFY2023FY2024FY2025FY2026

G&A expense (AUD Mn)

6.8335.1595.3134.867

R&D expense (AUD Mn)

3.2242.7003.2554.670

R&D tax incentive income (AUD Mn)

0.9501.0171.2681.782

Amortisation of hTERT and NETs intangibles (AUD Mn)

0.9450.9480.9450.945

Balance Sheet

MetricFY2022FY2023FY2024FY2025FY2026

Cash and equivalents (AUD Mn)

15.407.819.236.529.35

Total current assets (AUD Mn)

17.509.4010.908.7011.76

Total assets (AUD Mn)

30.8021.5021.7018.4620.45

Total current liabilities (AUD Mn)

1.801.521.531.511.26

Total liabilities (AUD Mn)

2.491.891.721.741.56

Total equity (AUD Mn)

28.3119.6119.9816.7118.89

Working capital (AUD Mn)

15.707.889.377.1910.50

Balance Sheet (AUD)

Line item (AUD)FY2025FY2026

Cash and cash equivalents

6,520,9239,353,441

Trade and other receivables (mainly R&D refund)

1,578,7812,022,882

Inventories

46,79437,736

Prepayments

555,840345,241

Building improvements, plant and equipment

953,607974,055

Intangible assets

8,678,7897,718,816

Right-of-use assets

122,4840

Total assets

18,457,21820,452,171

Trade and other payables

880,221761,119

Lease liability

162,2530

Equipment loan (current plus non-current)

213,936289,390

Provisions (current plus non-current)

486,374509,517

Total liabilities

1,742,7841,560,026

Net assets

16,714,43418,892,145

Issued capital

78,049,13587,652,051

Accumulated losses

-62,998,968-70,196,198

Key Financials (FY2025–FY2026)

MetricFY2025FY2026

Short-term debt incl. lease (AUD Mn)

0.2000.060

Long-term debt (AUD Mn)

0.1760.229

Total debt incl. lease (AUD Mn)

0.3760.289

Net cash (AUD Mn)

6.1459.064

Goodwill (AUD Mn)

00

Intangibles (AUD Mn)

8.6797.719

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Operating cash flow (AUD Mn)

-6.06-7.02-4.32-4.66-6.38

Capex (AUD Mn)

-0.412-0.292-0.174-0.104-0.168

Free cash flow (AUD Mn)

-6.47-7.31-4.49-4.77-6.55

Financing cash flow (AUD Mn)

16.90-0.275.912.059.39

Net change in cash (AUD Mn)

10.40-7.581.42-2.712.84

Dividends paid (AUD Mn)

00000

Buybacks (AUD Mn)

00000

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025FY2026

ROE (%)

-63.4-37.4-33.1-37.8-42.2

ROA (%)

-56.6-34.3-30.3-34.5-38.6

Current ratio (x)

9.726.187.125.759.37

Asset turnover (x)

0.0090.0150.0250.0270.022

Margin Analysis (%)

Ratio (FY2025 to FY2026)FY2025FY2026

Debt/equity (%)

2.31.5

R&D / revenue (%)

5941,081

Gross margin (%)

78.082.2

Product Lines — hTERT test

Product linePrimary geography of end-salesBasis

hTERT test (68% of FY2026 revenue)

United States

Sold directly to US laboratory customers; registered as a US Class I IVD

EXO-NET (32% of FY2026 revenue)

Invoiced to Promega (US-headquartered). End-customers are mainly in Europe, then North America, then Asia-Pacific.

Promega customer adoption commentary, AR FY2026

Geographic Revenue

Region (AUD)FY2024FY2025FY2026

Americas / Europe / APAC revenue split

000

Share Price and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Closing share price (AUD)

0.390.850.560.370.545

EPS (AUD)

-0.2003-0.0975-0.0709-0.0623-0.0569

Share Price History

DatePrice (AUD)Note

Feb 2021 (as BD1)

2.86

Intraday price on the day the founder lawsuit was announced (Stockhead)

8 Oct 2025

0.415

Last close before the placement

13 Oct 2025

0.35

Placement price

23 Jun 2026

0.565 (intraday high)

52-week high, during the run-up before EXO-OC data

30 Jun 2026

0.545

Last price before the halt

2 Jul 2026

0.27

After the EXO-OC update

1 Sep 2026

0.18

Per AR FY2026

Latest available

about 0.175 to 0.20

InvestSMART (quote dates not specified)

Approximate Change by Period

PeriodApproximate change

1-year (Oct 2025 to Oct 2026)

about -55% to -58%

3-year (about A$0.58 to A$0.61 in Oct 2023)

about -70%

5-year (vs. A$2.86 in early 2021)

more than -90%.

Calendar 2026 year to date (A$0.39 start)

about -50%

Valuation Snapshot

MetricValue

Market capitalisation

about A$24.6m

Net cash (30 Jun 2026)

A$9.06m (cash A$9.35m less debt A$0.29m). Current cash is likely lower after Q1 FY2027 burn.

Enterprise value

about A$15.6m (based on June 2026 net cash)

EV/Sales (FY2026)

about 36x

P/E

Not meaningful (loss-making)

EV/EBITDA

Not meaningful (EBITDA negative)

P/B

about 1.3x (book equity A$18.89m)

P/NTA

about 2.2x (NTA about A$11.17m, or about A$0.08 per share; InvestSMART also shows NTA per share of A$0.08)

Peer multiples

ASX micro-cap diagnostics peers are mostly loss-making and are typically valued on cash backing and pipeline; comparable EV/Sales multiples are not meaningful.

Capital Markets

ItemStatus

Dividend history

No dividends have ever been declared or paid, including FY2025 and FY2026

Dividend policy

None (pre-profit biotech)

Buyback

No on-market buyback in place (AR FY2026)

Capital raised (recent)

FY2022 about A$16.9m net; FY2024 A$7m placement plus SPP (A$2.4m received July 2024); FY2026 A$10.2m (placement plus SPP), A$9.6m net of costs

Options outstanding

6,075,000 unlisted IOP options (1 Sep 2026); 9,753,913 listed options expired 8 Jul 2026

Credit ratings (Moody's, S&P, Fitch)

Not rated

Debt maturity profile

Equipment loan only: A$60,390 current and A$229,000 non-current at 30 June 2026. No bonds or bank facilities.

Analyst Conclusions

Management guidance

  • No financial guidance has been issued.

  • hTERT revenue is expected to be flat in FY2027.

  • The FY2027 operational focus is: independent EXO-OC validation using controlled samples (single provider, nested prospective study or real-world study); LDT readiness and US CLIA laboratory partnering; CAR-exosome manufacturing readiness (GMP cells, CDMO); and first-in-human studies targeted for 2028.

Consensus expectations

No consensus revenue or earnings forecasts are publicly available. A one-analyst target of A$0.50 (TipRanks, late 2025) predates the July 2026 setback and should be treated as stale.

Bull case

  1. The platform is validated by a strong partner. Promega's continued orders and a customer base growing from about 60 to 90 in one year suggest EXO-NET has real scientific utility. That underpins credibility for EXO-OC and the CAR-exosome programs, which are built on the same technology.

  2. The EXO-OC failure was about the samples, not the test. Single-site data (100% Stage I/II sensitivity at 99.6% specificity) and the optimised algorithm (92.3% and 92.5% at 98% specificity) remain strong. The failure was traced to degraded biobank samples from one provider that supplied 69% of cancer cases. A controlled-protocol study could restore the thesis, and the high-risk LDT entry point is commercially reachable.

  3. The valuation reflects cash, not the pipeline. At about A$15.6m EV, the market ascribes little value to a therapeutic platform with in vivo TNBC efficacy, three CAR-exosome indications, 29 granted patents and the neuCA15-3 asset. A partnering deal for any one asset could re-rate the stock.

Bear case

  1. Funding and dilution. Operating burn of about A$6.4m a year against A$9.35m in cash points to a raise around 2027. At current prices, a A$10m raise could dilute holders by roughly 40% or more. Weak SPP take-up in 2025 suggests limited retail appetite.

  2. The evidence gap is widening. EXO-OC still lacks independent validation more than a year after its headline data. Ovarian screening has a history of disappointing trials, and the move to high-risk populations narrows the near-term market. LDT partners will require robust, multi-site validation that has yet to be generated.

  3. The commercial base is eroding. Product revenue fell 21% in FY2026. hTERT is in structural decline and EXO-NET revenue is volatile and still under A$0.3m after nearly four years on the market. Annual amortisation of about A$0.95m on legacy intangibles also creates impairment risk.

Key catalysts and monitorables (next 12 months)

Catalyst / monitorableExpected timingWhy it matters
Design and launch of the new EXO-OC validation study (sample source, size, partner)FY2027 H1 to H2Determines credibility and timeline to LDT
Announcement of a US CLIA laboratory partnerFY2027Converts EXO-OC into a commercial pathway
CAR-exosome CDMO selection and GMP readiness; dual-action CAR-exosome dataFY2027Gating items for the 2028 first-in-human target
Quarterly Appendix 4C reports (Oct 2026, Jan 2027, Apr 2027)QuarterlyCash burn and runway
Receipt of the FY2026 R&D tax refund (A$1.78m)Coming monthsLiquidity
2026 AGM (approximately November 2026)Nov 2026Board votes, remuneration, any capital-management resolutions
EXO-NET order flow from Promega; EXO-NET/RNA product launchOngoingEvidence of a recurring revenue base
neuCA15-3 automated platform transfer and partneringFY2027Optionality on a secondary asset
Capital raising or strategic transaction (possibly involving Tian An Medicare)2027 likelyDilution and control dynamics

Concluding analyst verdict

INOVIQ, formerly BARD1 Life Sciences, is a scientifically credible but commercially early-stage exosome platform company. Its investment case has become meaningfully riskier over the past six months. Since the 2020 Sienna merger, the company has executed reasonably well at the technology level. It built the EXO-NET isolation platform, secured Promega as global distributor, accumulated 29 granted patents, generated peer-reviewed validation for neuCA15-3 and CAR-exosome manufacturing, and produced in vivo efficacy for a cell-free CAR therapy in TNBC. It has also maintained a disciplined cost base by biotech standards, with annual losses of A$6.5m to A$7.5m and a debt-free balance sheet.

The core problem is that none of these achievements has yet turned into meaningful revenue or a validated clinical product. Product revenue of A$0.43m in FY2026 fell 21%. The flagship EXO-OC program, which the October 2025 A$10.2m raise was specifically designed to accelerate, suffered a validation failure in July 2026. The root cause appears to be external sample quality rather than test performance, but the practical result is roughly a year's delay, about A$0.85m of sunk cost and a halved share price. With A$9.35m of cash at June 2026 and an annual operating burn above A$6m, the company is likely to need fresh capital in 2027, probably at prices well below the 2025 placement.

The current valuation of about A$25m market capitalisation and about A$15m EV already discounts much of this. The stock trades at a modest premium to book and roughly twice tangible assets, so any partnering success, whether a US LDT laboratory for EXO-OC or a therapeutic licensing deal, would be disproportionately value-accretive. The presence of a 10% strategic holder, Tian An Medicare, and a chairman linked to that holder adds both financing optionality and possible corporate-activity angles.

Verdict: a high-risk, binary-catalyst speculative holding. The next 12 months will turn on two tests: whether management can design and fund an independent EXO-OC validation that satisfies US laboratory partners, and whether CAR-exosome manufacturing readiness attracts pharma interest. Until either is delivered, dilution risk dominates. Investors should key positioning to the quarterly cash reports and to any partner announcement, rather than to the headline sensitivity figures.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleAppointedBackground and educationOther current listed boardsCommittees

Peter Gunzburg

Non-Executive Chairman

Director 20 Oct 2025; Chairman 18 Dec 2025

40+ years as public company director, stockbroker and investor. BCom (UWA). Chairman of BARD1 2016 to 2020. Former director of Australian Stock Exchange Ltd, Eyres Reed and CIBC World Markets Australia.

Chairman, Metals X (ASX: MLX); NED, First Tin Plc (LSE: 1SN)

Not specified in excerpts

Dr Geoffrey Cumming

Non-Executive Director

28 Jul 2020

BSc (Hons), BAppSc, PhD, MBA, MAICD. Former MD of Roche Diagnostic Systems (Oceania), CEO of Biosceptre International, MD/CEO of Anteo Diagnostics. Former Chairman of Sienna Cancer Diagnostics.

NED, Anteo Diagnostics (ASX: ADO)

Chair, Remuneration; member, Audit & Risk

Robert (Max) Johnston

Non-Executive Director

17 Jun 2019

11 years as President and CEO of Johnson & Johnson Pacific; earlier roles at Diageo and Unilever. Former chair or director of Probiotec, AusCann, PolyNovo, Medical Developments International, Enero and Tissue Repair.

NED, Neurotech International (ASX: NTI)

Member, Remuneration and Audit & Risk

Philip Powell

Non-Executive Director

17 Jun 2019

BComm (Hons), ACA, MAICD. Chartered accountant and investment banker; 10 years at OAMPS, 10 years at Arthur Andersen. Former NED of RMA Global, PolyNovo and Medical Developments International.

None currently

Chair, Audit & Risk

Mary Harney

Non-Executive Director

1 Oct 2024

IDP-C INSEAD, BSc, BA (Fine Arts), MAICD, FIML. Director of Mary Harney Advisory. Former Chair of Race Oncology and Microbio.

Chair, Oncology One Pty Ltd (private)

Not specified in excerpts

David Williams (former)

Non-Executive Chairman

29 Nov 2023 to 18 Dec 2025 (resigned)

Investment banker and MD of Kidder Williams; Chairman of RMA Global; former Chairman of PolyNovo.

——

Executive Leadership Team

NameTitleAppointedBackground / education

Dr Leearne Hinch

Chief Executive Officer

7 Nov 2016

BSc, BVMS, MBA (Distinction). Founder of the Ingeneus Solutions consultancy. Roles at HealthLinx, OBJ, Holista Colltech, Chemeq, Virbac and Mars Petcare UK. Led the Sienna acquisition and the pivot to exosomes.

Mark Edwards

CFO and Company Secretary

2 Nov 2022

BAcc, CA. Eight years as CFO and Company Secretary at Medical Developments International; Head of Finance at Cogstate; 14 years at EY.

Dr Rebecca Lim

Chief Scientific Officer

12 Jan 2026

BSc (Hons), PhD. Former Director of Strategic Alliances at CTMC (an MD Anderson and National Resilience CDMO joint venture); SVP Scientific Affairs at Prescient Therapeutics; A/Prof at Monash University.

Prof Gregory Rice

Founding Scientist and Advisor

20 Sep 2021

PhD, BSc (Hons) (UWA), MHA, Grad Dip Mgt. More than 280 publications. Former Director of the UQ Centre for Clinical Diagnostics; co-founder and CSO of HealthLinx; CEO of Pregnostica SpA.

Emma Ball

Chief Commercial Officer

—

Listed by Statbase aggregator; not shown as KMP in AR FY2026

“—” = not publicly disclosed.

Directors' Remuneration

KMPYearSalary / feesBonusSuperLong-termShare-based paymentsTotal

P Gunzburg (Chair)

FY2026

57,21906,8660064,085

D Williams (former Chair)

FY2026

45,04505,4050-426,460-376,010

D Williams (former Chair)

FY2025

90,090010,3600634,922735,372

G Cumming (NED)

FY2026

60,00007,200022,90590,105

P Powell (NED)

FY2026

60,00007,200022,90590,105

M Johnston (NED)

FY2026

60,00007,200022,90590,105

M Harney (NED)

FY2026

60,00007,200022,90590,105

L Hinch (CEO)

FY2026

449,946030,00010,99522,907513,848

L Hinch (CEO)

FY2025

430,19390,00029,93210,37260,839621,336

M Edwards (CFO)

FY2026

294,639030,0006,79111,774343,204

G Rice (Founding Scientist)

FY2026

224,321026,0625,52511,781267,689

R Lim (CSO, part year)

FY2026

130,389014,6832389,319154,629

Total KMP

FY2026

1,441,5590141,81623,549-279,0591,327,865

Total KMP

FY2025

1,234,914147,303124,25921,312789,5172,317,305

Major Shareholders

HolderShares%

Tian An Medicare Limited (HKEX: 0383)

14,285,71410.15

Merchant Funds Management Pty Ltd

9,183,9196.52

Major Shareholders by Rank

RankHolderShares%
1

BNP Paribas Noms Pty Ltd (custodian; likely includes the Tian An stake)

14,737,87110.47
2

The Trust Company Australia Ltd (MOF A/C)

7,201,2865.12
3

Dr Irmgard Irminger-Finger (BARD1 founder)

2,860,0002.03
4

Lawn Views Pty Ltd (Angela Williams Family A/C)

2,676,9241.90
5

DS Shares Pty Ltd

1,700,0001.21
6

Lesamourai Pty Ltd

1,500,0001.07
7

Supergun Pty Ltd (Bricklanding Super Fund)

1,321,0000.94
8

Citicorp Nominees Pty Ltd

1,291,9810.92
9

Trovex Pty Ltd

1,250,1430.89
10

Palmers Plumbing & Hardware Pty Ltd

1,250,0000.89

Directors' Shareholdings

DirectorOrdinary sharesESS optionsListed options

Peter Gunzburg

3,693,0000315,000

Max Johnston

990,024250,000100,000

Philip Powell

670,344250,00030,000

Geoffrey Cumming

237,414250,00030,000

Mary Harney

60,000250,0000

Competitive Landscape

Key Competitors

CompetitorRelevant offeringScale (indicative)Positioning versus INOVIQ

Thermo Fisher Scientific (US)

Total Exosome Isolation reagents, Invitrogen EV kits

Group revenue about US$43bn (CY2024)

Huge channel and brand; reagent-based precipitation

Qiagen (NL/DE)

exoRNeasy / exoEasy kits

Group revenue about US$2.0bn (CY2024)

Strong in RNA workflows, which competes with the EXO-NET/RNA combination product

Bio-Techne (US)

Exosome Diagnostics (ExoDx) platform and reagents

Group revenue about US$1.2bn (FY Jun 2025)

Integrated EV diagnostics and reagents

Izon Science (NZ, private)

qEV size-exclusion columns

—

A de facto standard in EV research labs

System Biosciences (US, private)

ExoQuick precipitation

—

Long-established low-cost reagent

Miltenyi Biotec (DE, private)

MACSPlex / immunocapture EV kits

—

Immunoaffinity capture

“—” = not publicly disclosed.

Key Competitors — Roche Diagnostics

CompetitorRelevant offeringPositioning

Roche Diagnostics

Elecsys CA125 and HE4 (ROMA)

Entrenched incumbent biomarkers; EXO-OC itself incorporates CA125

Fujirebio

Lumipulse CA125, HE4, ROMA

Incumbent IVD assays

Aspira Women's Health (US)

Ova1, Overa, OvaWatch (adnexal mass risk assessment)

The closest US commercial ovarian blood-test comparator; a small-cap with persistent losses

GRAIL (US)

Galleri multi-cancer early detection

Includes ovarian signals; well funded; LDT model

Exact Sciences (US)

Multi-cancer early detection (Cancerguard)

Large commercial footprint

Mainstream CA15-3 assay suppliers (Roche, Abbott, Siemens Healthineers)

CA15-3 monitoring assays

Incumbents that neuCA15-3 seeks to improve on

Key Competitors — Pacific Edge

CompetitorRelevant offeringPositioning

Pacific Edge (NZ, NZX: PEB)

Cxbladder urine tests

Molecular urine test; the company has faced US reimbursement challenges

Abbott

UroVysion FISH

Incumbent cytology adjunct

Newer molecular urine tests

Various

Cited by management as new competition for hTERT

Key Competitors — Evox Therapeutics

CompetitorStatusPositioning

Evox Therapeutics (UK, private)

Engineered exosome drug delivery

Well-funded EV therapeutics peer

Capricor Therapeutics (US)

Exosome platform alongside a cell therapy lead

Listed EV-adjacent peer

Codiak BioSciences (US)

Engineered exosomes

Filed for bankruptcy in 2023; a cautionary precedent for EV therapeutics funding

CAR-NK and CAR-T developers (e.g., Nkarta, Fate Therapeutics)

Cell-based therapies

INOVIQ positions CAR-exosomes as a cell-free, off-the-shelf alternative

Peer Comparison FY2026

MetricINOVIQ (FY Jun 2026)Bio-Techne (FY Jun 2025)Qiagen (CY2024)Aspira Women's Health (CY2024)

Revenue

A$0.43m

about US$1.2bn

about US$2.0bn

about US$9m (indicative)

Revenue growth

-21.1%

low single digit

low single digit

—

Gross margin

82.2%

about 65 to 70%

about 65% (adjusted)

—

Operating margin

about -1,500% (derived)

positive

positive

strongly negative

R&D intensity

1,081% of revenue

about 8 to 10%

about 9 to 10%

high

Company Snapshot

$0.3M

Revenue

1983

Founded

Victoria, Australia

Headquarters

SWOT Analysis

Strengths

  • Patent-protected platform: 29 granted patents and 11 pending across NETs, exosome therapeutics, SubB2M, BARD1 and hTERT at 30 June 2026 (AR FY2026).
  • Tier-1 distribution partner: Promega distributes EXO-NET worldwide, has placed three orders, and grew the customer base to 90 by June 2026 (AR FY2026).
  • Strong early EXO-OC data: 100% Stage I/II sensitivity at 99.6% specificity (498 samples, June 2025). The optimised algorithm reached 92.3% Stage I/II sensitivity at 98% specificity (AR FY2026).
  • Therapeutic in vivo proof of concept: 61.5% tumour burden reduction in a TNBC mouse model with no observed adverse effects (22 December 2025).
  • Clean balance sheet: A$9.35m cash, total debt of only A$0.29m, and a current ratio of 9.4x at 30 June 2026.
  • Non-dilutive funding support: the FY2026 R&D Tax Incentive accrual of A$1.78m covers about 38% of R&D expense.
  • High product gross margins: 82.2% in FY2026.

Weaknesses

  • Minimal revenue: A$0.43m in FY2026, down 21.1%. Product revenue covers under 5% of operating expenditure.
  • Persistent losses: net losses of A$6.5m to A$7.5m a year from FY2024 to FY2026; accumulated losses of A$70.2m.
  • Declining legacy product: hTERT revenue fell from A$363k (FY2023) to A$294k (FY2026), and management guides flat.
  • EXO-NET volatility: revenue fell 45.5% in FY2026 because of channel stocking, showing dependence on one distributor's ordering pattern.
  • Thin team: aggregators report 5 to 15 employees. A large share of R&D is outsourced (A$2.82m to contractors in FY2026), which creates key-person risk.
  • Weak retail support for raises: the October 2025 SPP raised only about A$0.7m against a A$2m target.
  • Execution miss on FY2026 priorities: no diagnostic partnership was signed, and EXO-OC validation was not completed.

Opportunities

  • US LDT pathway for EXO-OC in high-risk women (BRCA1/2, Lynch syndrome), a defined and reachable population with high unmet need.
  • Average-risk screening IVD: management cites 243m addressable women globally, a long-dated but very large option.
  • CAR-exosome partnering: data now covers TNBC, NSCLC and ovarian models. Pharma interest in cell-free CAR modalities could support out-licensing.
  • neuCA15-3 partnering once the assay moves to an automated chemiluminescent platform.
  • EXO-NET/RNA combination products with Promega for automated workflows, plus customNET deals in cardiology and neurology.
  • Strategic investor leverage: Tian An Medicare (10.15%) could open Asian partnerships or provide follow-on capital.

Threats

  • Clinical validation risk has already materialised: the 1,200-sample study was unusable, costing about A$850k and roughly a year of delay.
  • Financing and dilution: operating burn of A$6.38m in FY2026 against A$9.35m cash implies a likely raise within 12 to 18 months, at depressed prices (A$0.175 to A$0.20 versus A$0.35 at the October 2025 placement).
  • Competition from well-capitalised players in EV tools (Thermo Fisher, Qiagen, Bio-Techne) and early detection (GRAIL, Exact Sciences).
  • Regulatory and reimbursement uncertainty: INOVIQ has not yet formally engaged the TGA, FDA or EU Notified Bodies on regulatory pathways (AR FY2026 risk section).
  • Investor sentiment: the share price fell about 50% on 1 July 2026, and the June 2026 rally before the data drew an ASX price query.
  • FX exposure: USD revenue and costs are unhedged (AR FY2026).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
1 Apr 2025Research collaboration with UQ (Prof Salomon Gallo) on ovarian exosomal biomarkersStrengthens the EXO-OC biomarker pipeline
May 2025neuCA15-3 validation published in *Breast Cancer Research and Treatment*Peer-reviewed support for the SubB2M diagnostic
2 Jun 2025EXO-OC: 100% Stage I/II sensitivity and 77% all-stage sensitivity at 99.6% specificity (498 samples)Strong headline data that underpinned the later raise
FY2025 (reported Aug 2025)CAR-exosomes kill 88% of TNBC and NSCLC cells in vitroInitial therapeutic proof of concept
Mid-2025Promega EXO-NET customer base reaches about 60Channel traction
22 Aug 2025FY2025 Appendix 4E: revenue A$547,575 (+2.3%), net loss A$6.93m, cash A$6.52mFunding need flagged
18 Sep 2025CAR-exosome in vitro TNBC data: more than 90% killing within 10 hoursTherapeutic momentum
18 Sep 2025FY2025 Annual Report releasedStatutory
26 Sep 2025Exclusive worldwide licence from UniQuest for ovarian exosomal biomarkersIP consolidation for EXO-OC
1 Oct 2025JoVE publication on CAR-exosome activity and EXO-ACE™ manufacturingScientific validation
9 Oct 2025Trading halt pending capital raisingProcedural
13 Oct 2025A$9.5m placement at A$0.35 (15.7% discount); Tian An Medicare commits A$5m; SPP launchedFunds EXO-OC validation and LDT plus CAR-exosome work
16 to 17 Oct 2025Placement settled (27m+ shares); SPP booklet lodgedProcedural
20 Oct 2025Peter Gunzburg appointed Non-Executive DirectorCornerstone-linked board seat
Nov 2025SPP raises about A$0.7m, below the A$2m target; total raise A$10.2mWeak retail take-up at a time when shares traded near the offer price
Nov 20252025 AGM; Remuneration Report passed with 93.89%Governance
18 Dec 2025Chairman David Williams resigns; Gunzburg becomes Chairman; executive options granted at A$0.506Leadership change
22 Dec 2025In vivo CAR-NK-EV TNBC data: 61.5% tumour burden reduction versus 24.5% for unmodified EVs; no adverse effectsKey preclinical milestone
12 Jan 2026Dr Rebecca Lim appointed CSOAdds CDMO and IND expertise for therapeutics
Jan 2026Quarterly Business Update and Appendix 4C (December 2025 quarter)Statutory
Feb 2026Appendix 4D and FY2026 half-year reportStatutory
FY2026Promega places its third EXO-NET orderChannel continuity
Apr 2026EXO-OC sample analysis begins (about 1,200 samples, five biorepositories)Clinical execution
28 Apr 2026March 2026 quarterly report and Appendix 4CStatutory
29 May 2026EXO-OC provisional patent converted to a PCT international applicationIP protection
17 Jun 2026Response to ASX price query: the share price rise was attributed to a third-party research note on upcoming milestonesSpeculative run-up ahead of data
Jun 2026 (AR says 6 Jun; ASX release appears after 17 Jun)CAR-exosomes kill more than 90% of ovarian cancer cells in vitro (CA125 and EGFR targeting)Platform expansion. Release date discrepancy between AR FY2026 and the ASX feed noted.
26 Jun 2026Notification of cessation of securitiesProcedural
29 Jun 2026Trading halt pending EXO-OC updateProcedural
1 Jul 2026EXO-OC study update: 1,200 samples unsuitable (degradation, variability); improved algorithm data releasedMajor setback. Share price falls about 50%, from A$0.545 to A$0.27.
8 Jul 20269,753,913 listed options (from the 2024 raise) expireRemoves overhang
13 Jul 2026June 2026 quarterly report: cash A$9.353m; failed study cost about A$850kFunding update
14 Jul 2026EXO-OC study outcome investor webinarInvestor communication
15 Jul 2026Change of director's interest noticeDirector buying after the fall
6 Aug 2026Becoming a substantial holder noticeRegister change (holder not identified in sources reviewed; Merchant Funds Management appears as substantial at 1 Sep 2026)
27 Aug 2026FY2026 Appendix 4E and Appendix 4G / Corporate Governance Statement: net loss A$7.51m, cash A$9.35mStatutory
17 Sep 2026FY2026 Annual Report releasedStatutory

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

2 charts
Revenue by Segment (AUD): Total product revenue rose from AUD 398,193 in FY2023 to AUD 432,047 in FY2026.
INOVIQ Limited — Revenue by Segment (AUD)
Series (AUD)FY2023FY2024FY2025FY2026
Total product revenue398,193535,118547,575432,047
hTERT test revenue363,209333,255294,314294,002
EXO-NET revenue34,984201,863253,261138,045

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.